Core Insights - Kite, a Gilead Company, presented new analysis showing that second-line Yescarta® therapy provides consistent benefits for patients with relapsed/refractory large B-cell lymphoma, even for those ineligible for high-dose chemotherapy followed by autologous stem cell transplant [1] Summary by Categories - **Company Performance** - The analysis is based on a combined four-year data set, indicating the effectiveness of Yescarta® in a challenging patient population [1] - **Industry Impact** - The findings suggest a shift in treatment paradigms for relapsed/refractory large B-cell lymphoma, highlighting the potential of CAR T-cell therapies like Yescarta® in improving patient outcomes [1]